The Novel Oral Administration Isoliquiritigenin-Protein/Zein Nanodrug Targeting for Triple-Negative Breast Cancer Treatment
Grant Data
Project Title
The Novel Oral Administration Isoliquiritigenin-Protein/Zein Nanodrug Targeting for Triple-Negative Breast Cancer Treatment
Principal Investigator
Dr Chen, Jianping
(Project Coordinator (PC))
Co-Investigator(s)
Dr Zhang Jinming
(Co-Investigator)
Mr Gao Fei
(Co-Investigator)
Dr Li Peng
(Co-Investigator)
Miss Liu Qingqing
(Co-Investigator)
Miss Yue Sui
(Co-Investigator)
Duration
24
Start Date
2020-08-01
Completion Date
2022-07-31
Amount
4999314
Conference Title
The Novel Oral Administration Isoliquiritigenin-Protein/Zein Nanodrug Targeting for Triple-Negative Breast Cancer Treatment
Keywords
Isoliquiritigenin-Protein/Zein Nanodrug, Novel Oral Administration, Triple-Negative Breast Cancer Treatment
Discipline
Others - Medicine, Dentistry and Health
HKU Project Code
MRP/027/18X
Grant Type
Midstream Research Programme for Universities (MRP)
Funding Year
2020
Status
Completed
Objectives
Triple-negative breast cancer (TNBC) remains a disease with poor prognosis and limited treatment options and is not amenable to hormone therapy or HER2-targeting therapy. Meanwhile, the chemotherapy and radiotherapy in TNBC treatment could lead to some serious lesions or even death. Therefore, our group focused on the anti-TNBC active compound isoliquiritigenin (ISL) and its mechanisms in depth. ISL is a dietary compound can be isolated from Spatholobus Suberect (SS) with good effects and low toxicity. However, the poor solubility and low bioavailability of ISL are the major challenges in translational medicine. So, it's necessary to develop a new preparation with good stability to solve those problems. Here, we have designed a novel oral administration isoliquiritigenin-zein nanoparticle (ISL/zein NP) with targeting and increasing efficacy by using an electrosprayingelectrospinning system. Compared with the traditional forms of preparation, the advantages of nano-preparation are obvious, such as improved solubility, good targeting ability. Meanwhile, this ISL/zein NP is designed to be delivered by oral administration, which is superior to the common nano-preparation system by intravenous administration in terms of improving patients' compliance and decreasing the adverse reaction. In this project, the targeted oral administration nano-drug of ISL/zein NP will be further developed and optimized, including the preparation and identification of ISL/zein NPs, quality control and pharmacological effects on TNBC in vitro and in vivo.